Orexo
Orexo AB is a Swedish specialty pharmaceutical company developing formulations for substance use disorders and digital therapeutics. The company formulates and commercializes sublingual prescription drugs using its AmorphOX technology platform, featuring lead product Zubsolv for opioid use disorder. Principal revenues derive from commercial sales of prescription pharmaceuticals alongside licensing royalties and digital health product sales. Core end markets encompass addiction treatment clinics, psychiatry practices, specialty pharmacies, and healthcare payers in the United States and Europe. Orexo holds an established market position in the US addiction medicine sector through its commercialized prescription therapies. The company is headquartered in Uppsala, Sweden, and its ordinary shares trade on the Nasdaq Stockholm exchange.
2 of the funds FundTelligence covers report a position in Orexo.
- Legal name
- OREXO AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 2
Funds holding Orexo
- Storebrand Sverige Småbolag Plus — Storebrand · 0.01 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)